Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 16, 2019

Merck’s keytruda cuts death risk in oesophageal cancer

Merck has reported positive results from the Phase III KEYNOTE-181 clinical trial of its keytruda drug in previously treated patients with advanced oesophageal or oesophagogastric junction carcinoma.

Merck has reported positive results from the Phase III KEYNOTE-181 clinical trial of its keytruda drug in previously treated patients with advanced oesophageal or oesophagogastric junction carcinoma.

Keytruda is an anti-PD-1, humanised monoclonal antibody designed to boost the immune system’s ability to identify and fight tumour cells.

The drug met the primary endpoint of significant improvement in overall survival (OS), leading to 31% decrease in the risk of death compared to chemotherapy.

The improved OS was observed in squamous cell carcinoma or adenocarcinoma patients who progressed after undergoing standard therapy and whose tumours expressed PD-L1.

However, patients with squamous cell histology and in the entire intention-to-treat (ITT) trial population did not achieve directionally favourable, statistical significance for OS.

“Along with other new data for keytruda and from our broad oncology portfolio, we are pleased to share our latest clinical research.”

Merck will present the trial results at the 2019 Gastrointestinal Cancers Symposium.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Merck Research Laboratories chief medical officer Roy Baynes said: “Oesophageal cancer often progresses aggressively, so we are encouraged to see these overall survival results for keytruda as monotherapy in previously treated patients.

“Along with other new data for keytruda and from our broad oncology portfolio, we are pleased to share our latest clinical research in gastrointestinal cancers at ASCO GI.”

The randomised, open-label KEYNOTE-181 trial assessed the drug as monotherapy for the second-line treatment in a total of 628 patients.

Primary endpoint of the trial is OS, while secondary endpoints are progression-free survival (PFS), objective response rate (ORR) and safety/tolerability.

Merck’s clinical research programme for keytruda includes more than 900 trials across various cancers and treatment settings. The programme aims to gain better insights into the drug’s role across cancers as well as factors that could help predict a patient’s response to its therapy.

The drug is also being studied for oesophageal cancer treatment in a Phase III KEYNOTE-590 trial.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU